In cancer, CX3CL1 has been shown to modulate antitumor immunity by promoting the recruitment and cytotoxic activity of NK cells and CD8+ T cells.[54,55] CCR2 is a chemokine receptor primarily expressed on monocytes, macrophages, and subsets of T cells. Here, CD8A is linked to cancer.